Altogether, these results suggest that the combination of a PI3Ki with a CDK4/6i, with or without ET, is a valid therapeutic option for the treatment of ER+ BC tumors after progression on CDK4/6i plus ET, independently of PIK3CA, ESR1 mutation status or pRb expression. The gene discussed is ESR1; the disease is breast cancer.